MétaCan
Menu
Back to cohort
Record W4416328850 · doi:10.1158/1078-0432.ccr-25-1834

Clinicogenomic Characterization of Primary Sclerosing Cholangitis–Associated Biliary Tract Cancers

2025· article· en· W4416328850 on OpenAlexafffund
Xin Wang, Jaime Haro-Silerio, Felix E.G. Beaudry, Ayelet Borgida, Farnoosh Abbas‐Aghababazadeh, Nasim Bondar. Sahebi, Michael Wang, Daniel P. Fox, Mohamed Nuh, Monica Hsiang, Deepak Bhamidipati, Hyunseon C. Kang, Veronica Cox, Ethan B. Ludmir, Eugene J. Koay, Lawrence N. Kwong, Kimana Quentin, Deyali Chatterjee, Yun Shin Chun, Hop S. Tran Cao, Funda Meric‐Bernstam, Ian Hu, Anna Dodd, Oumaima Hamza, Maggie Hildebrand, Roxana Bucur, Gideon M. Hirschfield, Arndt Vogel, Grainne M. O’Kane, Steven Gallinger, Benjamin Haibe‐Kains, Faiyaz Notta, Gonzalo Sapisochín, Jennifer J. Knox, Milind Javle, Sunyoung S. Lee, Robert C. Grant

Bibliographic record

VenueClinical Cancer Research · 2025
Typearticle
Languageen
FieldMedicine
TopicLiver Diseases and Immunity
Canadian institutionsPrincess Margaret Cancer FoundationUniversity Health NetworkUniversity of TorontoToronto General HospitalPrincess Margaret Cancer CentreOntario Institute for Cancer Research
FundersTerry Fox Research InstituteCholangiocarcinoma FoundationPrincess Margaret Cancer Foundation
KeywordsBiliary tract cancerBiliary tractImmunotherapyPrimary sclerosing cholangitisRetrospective cohort studyClinical trialProspective cohort study

Abstract

fetched live from OpenAlex

PURPOSE: Biliary tract cancer (BTC) is the leading cause of death in patients with primary sclerosing cholangitis (PSC). PSC-related BTC is poorly understood, and the risks and benefits of conventional and immunotherapy treatments are unknown. We aimed to characterize clinical outcomes and genomes of PSC-related BTCs. EXPERIMENTAL DESIGN: This was a retrospective cohort study of patients with BTC with underlying PSC treated at MD Anderson Cancer Center (N = 46) and Princess Margaret Cancer Centre (N = 16), which were contrasted to patients with non-PSC-related BTC (N = 146). We compared outcomes between PSC and non-PSC, and PSC treated with and without immunotherapy. A combination of targeted sequencing (N = 139), whole-genome sequencing (WGS; N = 27), and WGS with paired RNA sequencing (N = 33) delineated the genomic and transcriptomic landscape of PSC-associated BTCs. RESULTS: In PSC-related BTC, the addition of immunotherapy to chemotherapy was associated with improved first-line progression-free survival (PFS; N = 22 vs. 11; median PFS, 12.2 vs. 4.7 months; P = 0.01). Immune-related adverse events were rare (N = 2, 12.5%) and improved after treatment discontinuation. Classic actionable genomic alterations, including IDH1 mutations and FGFR2 fusions, were absent in PSC-related BTCs. PSC tumors had a 2.6-fold higher tumor mutational burden (P = 3.28e-05) compared with non-PSC tumors. Transcriptomic profiling revealed a subset of PSC tumors displaying RNA signatures of immunotherapy response. CONCLUSIONS: Immunotherapy in PSC-associated BTCs seemed safe, with a potential signal of effectiveness. Given the sample size and retrospective design, these results are hypothesis-generating. Together, these results demonstrate the unique biology underlying PSC-associated BTCs, highlighting the need for prospective trials and the development of specialized treatment strategies.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.003

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.242
GPT teacher head0.504
Teacher spread0.261 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueClinical Cancer ResearchSame topicLiver Diseases and ImmunityFrench-language works237,207